



## GUJARAT TERCE LABORATORIES LIMITED

11<sup>th</sup> February, 2019

To,  
Corporate Relations Department,  
Bombay Stock Exchange Limited,  
2<sup>nd</sup> Floor, P.J Towers,  
Dalal Street,  
Mumbai-400 001

**Scrip Code: 524314**

Dear Sir,

**Subject: Outcome of Board Meeting**

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today i.e., on Monday, 11<sup>th</sup> February, 2019 which commenced at 12:30 p.m. and concluded at 02:40 p.m. inter alia, have approved / noted the following:-

1. Approval of Unaudited Financial Results (Standalone) for the Quarter and Nine Months' period ended December 31, 2018:

Upon recommendation of the Audit Committee, the Board of Directors have approved the Unaudited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (INDAS) for the Quarter and Nine Months' period ended December 31, 2018 (enclosed herewith) and the same is also available on the website of the company at [www.gujaratterce.com/Investor](http://www.gujaratterce.com/Investor)

2. Took note of the Limited Review Report of the Statutory Auditors on the Unaudited Financial Results (Standalone) for the Quarter and Nine Months' period ended December 31, 2018.

The Limited Review Report of the Statutory Auditors (USS & Associates) is with unmodified opinion with respect to the Unaudited Financial Results (Standalone) of the Company for the Quarter and Nine Months' period ended December 31, 2018 (enclosed herewith), the Board of Directors took note of the same.

3. Adopted and Amended "Policy for Determination of Legitimate Purposes" as part of Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information pursuant to Regulation 3(2A) of SEBI (Prohibition of Insider Trading) Regulations, 2015 which shall come into force w.e.f. April 01, 2019





## GUJARAT TERCE LABORATORIES LIMITED

4. Adopted "Policy of procedures for inquiry in case of leak of Unpublished price sensitive information", Pursuant to Regulation 9A (5) of SEBI (Prohibition of Insider Trading) Regulations, 2015 which shall come into force w.e.f. April 01, 2019
5. Adopted and amended Code of Conduct for prevention of Insider Trading pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 pursuant to SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 (w.e.f. April 01, 2019)

We request you to please take the above information on your records.  
Thanking you.

Yours faithfully,  
Gujarat Terce Laboratories Limited

**NATWARBHAI PARSOTTAM PRAJAPATI**  
Chairman and Managing Director  
DIN: 00031187



Encl.: Unaudited Financial Results with Limited Review Report for the quarter and nine month ended on 31<sup>st</sup> December, 2018.





# GUJARAT TERCE LABORATORIES LIMITED

GUJARAT TERCE LABORATORIES LTD.

CIN:L28112GJ1985PLC007753

Regd.Office: 122/2, Ravi Estate, Bileshwarpura, Chhatral, Dist. Gandhinagar, Gujarat

## Statement of Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2018

Sr. No.	Particulars	[Rs. In Lakhs except per share detail]					
		Quarter ended			Nine Months ended		Year ended
		31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
		Un Audited	Unaudited	Un Audited	Un Audited	Un Audited	Audited
	1	2	3	4	5	6	7
I.	Revenue from operations	830.53	796.37	771.99	2300.86	2034.76	2901.42
II.	Other income	0.26	1.13	0.22	1.99	2.86	41.32
III.	<b>Total Revenue (I+II)</b>	<b>830.79</b>	<b>797.50</b>	<b>772.21</b>	<b>2302.85</b>	<b>2037.62</b>	<b>2942.74</b>
IV.	Expenses:						
	a) Cost of Material consumed	103.40	60.96	122.30	245.73	222.76	244.32
	b) Purchase of stock in trade	202.62	186.73	189.87	613.33	508.30	816.02
	c) Changes in inventories of finished goods, WIP and stock in trade.	-25.45	59.96	-21.67	-10.02	42.82	-8.29
	d) Employees benefits expenses.	325.37	303.19	296.03	935.14	837.58	1192.77
	e) Finance Costs	4.74	9.49	2.84	15.29	17.85	22.6
	f) Depreciation and amortisation exp.	5.14	5.15	4.65	14.92	13.77	18.51
	g) Other Expenses	158.18	161.86	141.69	481.31	376.06	624.28
	<b>Total Expenses</b>	<b>774.00</b>	<b>787.34</b>	<b>735.71</b>	<b>2295.70</b>	<b>2019.14</b>	<b>2910.21</b>
V	<b>Profit/(Loss) before exceptional and Extra ordinary items and Taxes.(III - IV)</b>	<b>56.79</b>	<b>10.16</b>	<b>36.50</b>	<b>7.15</b>	<b>18.48</b>	<b>32.53</b>
VI	Exceptional items.	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit/(Loss) before extraordinary items and Tax (V-VI)</b>	<b>56.79</b>	<b>10.16</b>	<b>36.50</b>	<b>7.15</b>	<b>18.48</b>	<b>32.53</b>
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Profit/(Loss) before Tax (VII-VIII)</b>	<b>56.79</b>	<b>10.16</b>	<b>36.50</b>	<b>7.15</b>	<b>18.48</b>	<b>32.53</b>
X	Tax Expenses						
	1) Current Tax	0.00	0.00	0.00	0.00	0.00	9.98
	2) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-4.53
XI	<b>Profit/(Loss) for the period from continuing operations (IX-X)</b>	<b>56.79</b>	<b>10.16</b>	<b>36.50</b>	<b>7.15</b>	<b>18.48</b>	<b>27.08</b>
XII	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	36.49
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XIII	<b>Other Comprehensive Income for the period, net of tax</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>-29.02</b>
XIV	<b>Total Comprehensive Income for the period (XI+XII)</b>	<b>56.79</b>	<b>10.16</b>	<b>36.50</b>	<b>7.15</b>	<b>18.48</b>	<b>34.55</b>
XV	<b>Paid up Equity Capital (at par value of Rs. 10 each)</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>
XVI	Earning per equity share						
	a) Basic	0.77	0.14	0.49	0.10	0.25	0.46
	b) Diluted	0.77	0.14	0.49	0.10	0.25	0.46
	(See accompanying notes to the Financial Results)						

### Notes:

- The above Unaudited financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on February, 11, 2019.
- The Statutory Auditors have carried out the Limited Review of the above financial results of the Company for the quarter and nine month ended on December 31, 2018.
- The Company has adopted Indian Accounting Standard ("Ind AS") notified by the Ministry of Corporate Affairs with effect from April 01, 2017 and accordingly these financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- The Company is operating in single (Pharmaceutical) segment, so above results are for single segment only.
- To facilitate Comparison, figures of previous periods has been regrouped, wherever necessary.

Place: Ahmedabad

Date: 11/02/2019



For, Gujarat Terce Laboratories Limited

Natwarbhai P. Prajapati

Chairman and Managing Director

DIN: 00031187

**Regd. Office & Factory :** 122/2 Ravi Estate, Bileshwarpura, Chhatral, Ta. : Kalol, Dist. : Gandhinagar (Guj.) INDIA.  
Ph.: 02764-233182 ● E.mail : gtl.factory@gmail.com  
CIN : L28112GJ1985PLC007753

**Admn. Office :** D/801 & 802, The First, Behind Keshavbaug Party Plot, Near Shivalik High-street, Vastrapur, Ahmedabad-380015 Gujarat.(INDIA) ● Ph.: 079-48933701  
E.mail : ho@gujaratterce.com ● Web. : www.gujaratterce.com



## Limited Review Report

To,  
The Board of Directors,  
Gujarat Terce Laboratories Limited.

We have reviewed the accompanying statement of unaudited financial results of Gujarat Terce Laboratories Limited for the quarter and nine months ended December 31<sup>st</sup>, 2018 being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad  
Date: 11/02/2019

For, USS & Associates,  
Chartered Accountants



CA Ujal S. Mehta  
Designation: Proprietor  
Membership Number: 112337